SCHEMBL14084034

SCHEMBL14084034

CCOc1cccc(NC(=O)c2ccc(-c3ncccc3Cl)cn2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 2/20 0.48
▸ SCN2A Q99250 1/20 0.48
▸ SCN10A Q9Y5Y9 1/20 0.48
▸ KMT2A Q03164 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ NR1H4 Q96RI1 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ MITF O75030 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ TRPV1 Q8NER1 2/20 0.46
▸ FADS1 O60427 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14083930 0.89 GRM4 (0.62) GRM4KMT2ASMN1; SMN2LMNAHTT
SCHEMBL14084028 0.88 GRM4 (0.50) GRM4SCN2ASCN10AKMT2ASMN1; SMN2
SCHEMBL14083920 0.88 TRPV1 (0.60) KMT2ASMN1; SMN2LMNAHTTNR1H4
SCHEMBL14084033 0.88 NPC1 (0.61) KMT2ASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL14083992 0.86 RAB9A (0.63) KMT2ASMN1; SMN2LMNAHTTKDM4E
SCHEMBL14084016 0.84 P2RX1 (0.51) GRM4SCN2ASCN10AHTTNPC1
SCHEMBL14083913 0.83 GRM4 (0.60) GRM4KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL14083925 0.81 TRPV1 (0.47) GRM4KMT2ASMN1; SMN2LMNAHTT
SCHEMBL14083947 0.81 CSF1R (0.49) GRM4KMT2ASMN1; SMN2LMNANPC1
SCHEMBL14083912 0.81 TRPV1 (0.56) GRM4KDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof KELLY MICHAEL G 2008-08-21 — — US disclosed
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof KELLY MICHAEL G 2008-08-21 — — US disclosed
US-7338950-B2 Amide compounds as ion channel ligands and uses thereof RENOVIS, INC. (US) 2008-03-04 — — US disclosed
US-7338950-B2 Amide compounds as ion channel ligands and uses thereof RENOVIS, INC. (US) 2008-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof TRPV1, TRPA1, TRPV2 GRM4 362/4885SCN2A 61/4885SCN10A 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback